Atara Biotherapeutics (ATRA) Stock Forecast, Price Target & Predictions
ATRA Stock Forecast
Atara Biotherapeutics stock forecast is as follows: an average price target of $10.50 (represents a 23.38% upside from ATRA’s last price of $8.51) and a rating consensus of 'Sell', based on 1 wall street analysts offering a 1-year stock forecast.
ATRA Price Target
The average price target for Atara Biotherapeutics (ATRA) is $10.50 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $3.00. This represents a potential 23.38% upside from ATRA's last price of $8.51.
ATRA Analyst Ratings
According to 1 Wall Street analysts, Atara Biotherapeutics's rating consensus is 'Sell'. The analyst rating breakdown for ATRA stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 0 'Hold' (0.00%), 1 'Sell' (100.00%), and 0 'Strong Sell' (0.00%).
Atara Biotherapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 16, 2024 | Salim Syed | Mizuho Securities | $18.00 | $6.83 | 163.54% | 111.52% |
| Aug 09, 2022 | - | Goldman Sachs | $3.00 | $3.87 | -22.48% | -64.75% |
| May 24, 2022 | - | Goldman Sachs | $4.00 | $4.85 | -17.53% | -53.00% |
The latest Atara Biotherapeutics stock forecast, released on Aug 16, 2024 by Salim Syed from Mizuho Securities, set a price target of $18.00, which represents a 163.54% increase from the stock price at the time of the forecast ($6.83), and a 111.52% increase from ATRA last price ($8.51).
Atara Biotherapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $18.00 | $18.00 |
| Last Closing Price | $8.51 | $8.51 | $8.51 |
| Upside/Downside | -100.00% | 111.52% | 111.52% |
In the current month, the average price target of Atara Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Atara Biotherapeutics's last price of $8.51. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2022 | Goldman Sachs | Sell | Sell | Hold |
| May 24, 2022 | Goldman Sachs | Sell | Sell | Hold |
Atara Biotherapeutics's last stock rating was published by Goldman Sachs on Aug 09, 2022. The company gave ATRA a "Sell" rating, the same as its previous rate.
Atara Biotherapeutics Financial Forecast
Atara Biotherapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 15 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $4.25M | $2.14M | $957.00K | $1.23M | $221.00K | $4.46M | - | $7.31M | $7.55M | $5.37M | $3.87M | $3.55M | - | - | - |
| Avg Forecast | $3.00M | $2.30M | $1.60M | $60.85M | $17.33M | $30.07M | $37.09M | $24.69M | $2.56M | $5.09M | $4.36M | $32.01M | $34.01M | $5.13M | $6.84M | $5.79M | $31.38M | $4.55M | $4.95M | $2.05M | $15.00M | $1.02B | $1.05B |
| High Forecast | $4.15M | $3.18M | $2.21M | $84.16M | $23.96M | $33.99M | $51.30M | $34.15M | $3.02M | $7.04M | $6.03M | $44.27M | $47.03M | $7.10M | $6.84M | $8.62M | $46.74M | $6.77M | $7.37M | $3.06M | $22.35M | $1.23B | $1.26B |
| Low Forecast | $1.71M | $1.31M | $909.87K | $34.60M | $9.85M | $26.15M | $21.09M | $14.04M | $2.09M | $2.89M | $2.48M | $18.20M | $19.34M | $2.92M | $6.84M | $2.24M | $12.15M | $1.76M | $1.92M | $795.42K | $5.81M | $818.60M | $838.10M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 12 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | 1.66% | 0.42% | 0.22% | 0.04% | 0.01% | 0.87% | - | 1.26% | 0.24% | 1.18% | 0.78% | 1.73% | - | - | - |
Atara Biotherapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $24.69M, with a low forecast of $14.04M, and a high forecast of $34.15M. ATRA's average Quarter revenue forecast represents a 480.68% increase compared to the company's last Quarter revenue of $4.25M (Dec 23).
Atara Biotherapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 15 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 12 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | $-52.07M | $-69.61M | $-71.41M | $-75.02M | $-75.54M | $-83.25M | - | $-86.63M | $-93.40M | $-82.50M | $-81.68M | $-76.02M | $-81.70M | $-6.11M | $-9.31M |
| Avg Forecast | $-600.00K | $-460.00K | $-320.00K | $-12.17M | $-3.47M | $-6.01M | $-7.42M | $-84.01M | $-512.40K | $-1.02M | $-871.80K | $-89.85M | $-6.80M | $-106.43M | $-1.37M | $-96.10M | $-55.29M | $-84.14M | $-78.68M | $-81.08M | $-3.00M | $-10.84M | $-9.73M |
| High Forecast | $-341.20K | $-261.59K | $-181.97K | $-6.92M | $-1.97M | $-5.23M | $-4.22M | $-67.21M | $-418.29K | $-578.87K | $-495.76K | $-71.88M | $-3.87M | $-85.15M | $-1.37M | $-76.88M | $-44.23M | $-67.31M | $-62.95M | $-64.86M | $-1.16M | $-8.68M | $-7.78M |
| Low Forecast | $-829.80K | $-636.18K | $-442.56K | $-16.83M | $-4.79M | $-6.80M | $-10.26M | $-100.81M | $-604.42K | $-1.41M | $-1.21M | $-107.82M | $-9.41M | $-127.72M | $-1.37M | $-115.32M | $-66.35M | $-100.96M | $-94.42M | $-97.29M | $-4.47M | $-13.01M | $-11.67M |
| Surprise % | - | - | - | - | - | - | - | - | 101.62% | 68.39% | 81.92% | 0.83% | 11.11% | 0.78% | - | 0.90% | 1.69% | 0.98% | 1.04% | 0.94% | 27.23% | 0.56% | 0.96% |
undefined analysts predict ATRA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Atara Biotherapeutics's previous annual EBITDA (undefined) of $NaN.
Atara Biotherapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 15 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 12 | 13 |
| Net Income | - | - | - | - | - | - | - | - | $-60.45M | $-69.80M | $-71.11M | $-74.77M | $-74.57M | $-84.09M | - | $-87.99M | $-93.35M | $-84.66M | $-83.79M | $-78.33M | $-81.31M | $-14.95M | $-9.16M |
| Avg Forecast | $-468.10M | $-481.61M | $-496.35M | $231.90M | $-230.98M | $-105.66M | $-137.48M | $-85.67M | $-683.41M | $-956.42M | $-1.01B | $-91.62M | $-798.20M | $-109.43M | $-2.80B | $-97.99M | $-56.82M | $-86.50M | $-80.94M | $-83.44M | $-80.71M | $-15.28M | $-9.58M |
| High Forecast | $-205.62M | $-211.56M | $-218.03M | $347.36M | $-101.46M | $-80.44M | $-60.39M | $-68.54M | $-672.21M | $-420.12M | $-442.66M | $-73.30M | $-350.62M | $-87.54M | $-2.80B | $-78.40M | $-45.46M | $-69.20M | $-64.75M | $-66.76M | $-16.43M | $-12.23M | $-7.66M |
| Low Forecast | $-701.16M | $-721.40M | $-743.49M | $101.87M | $-345.98M | $-130.88M | $-205.93M | $-102.80M | $-694.61M | $-1.43B | $-1.51B | $-109.95M | $-1.20B | $-131.31M | $-2.80B | $-117.59M | $-68.19M | $-103.81M | $-97.12M | $-100.13M | $-132.09M | $-18.34M | $-11.49M |
| Surprise % | - | - | - | - | - | - | - | - | 0.09% | 0.07% | 0.07% | 0.82% | 0.09% | 0.77% | - | 0.90% | 1.64% | 0.98% | 1.04% | 0.94% | 1.01% | 0.98% | 0.96% |
Atara Biotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ATRA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Atara Biotherapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 15 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 12 | 13 |
| SG&A | - | - | - | - | - | - | - | - | $10.39M | $12.25M | $13.34M | $13.87M | $13.24M | $18.92M | - | $20.57M | $21.82M | $19.85M | $19.40M | $17.74M | $16.14M | $3.60M | $3.54M |
| Avg Forecast | $7.68M | $5.89M | $4.10M | $155.88M | $44.39M | $77.02M | $95.02M | $20.00M | $6.56M | $13.04M | $11.17M | $21.39M | $87.11M | $13.15M | $17.52M | $14.83M | $13.28M | $11.65M | $12.67M | $5.26M | $38.42M | $3.68M | $3.71M |
| High Forecast | $10.63M | $8.15M | $5.67M | $215.58M | $61.39M | $87.07M | $131.41M | $24.00M | $7.74M | $18.03M | $15.44M | $25.67M | $120.47M | $18.19M | $17.52M | $22.09M | $15.94M | $17.35M | $18.88M | $7.84M | $57.24M | $4.42M | $4.45M |
| Low Forecast | $4.37M | $3.35M | $2.33M | $88.64M | $25.24M | $66.98M | $54.03M | $16.00M | $5.36M | $7.41M | $6.35M | $17.11M | $49.54M | $7.48M | $17.52M | $5.74M | $10.62M | $4.51M | $4.91M | $2.04M | $14.88M | $2.95M | $2.96M |
| Surprise % | - | - | - | - | - | - | - | - | 1.58% | 0.94% | 1.19% | 0.65% | 0.15% | 1.44% | - | 1.39% | 1.64% | 1.70% | 1.53% | 3.37% | 0.42% | 0.98% | 0.96% |
Atara Biotherapeutics's average Quarter SG&A projection for Mar 24 is $20.00M, based on 2 Wall Street analysts, with a range of $16.00M to $24.00M. The forecast indicates a 92.55% rise compared to ATRA last annual SG&A of $10.39M (Dec 23).
Atara Biotherapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 15 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 12 | 13 |
| EPS | - | - | - | - | - | - | - | - | $-0.56 | $-0.66 | $-0.68 | $-0.72 | $-0.72 | $-0.82 | - | $-0.87 | $-0.96 | $-0.90 | $-0.91 | $-0.86 | $-0.95 | $-0.62 | $-0.42 |
| Avg Forecast | $-7.62 | $-7.84 | $-8.08 | $3.77 | $-3.76 | $-1.72 | $-2.24 | $-6.42 | $-11.13 | $-15.57 | $-16.40 | $-9.27 | $-12.99 | $-18.64 | $-19.90 | $-0.93 | $-0.69 | $-0.90 | $-0.87 | $-0.90 | $-0.75 | $-0.45 | $-0.46 |
| High Forecast | $-3.35 | $-3.44 | $-3.55 | $5.65 | $-1.65 | $-1.31 | $-0.98 | $-2.82 | $-10.94 | $-6.84 | $-7.21 | $-4.07 | $-5.71 | $-8.19 | $-19.90 | $-0.19 | $-0.14 | $-0.18 | $-0.18 | $-0.18 | $-0.15 | $-0.36 | $-0.37 |
| Low Forecast | $-11.41 | $-11.74 | $-12.10 | $1.66 | $-5.63 | $-2.13 | $-3.35 | $-9.61 | $-11.31 | $-23.32 | $-24.57 | $-13.88 | $-19.46 | $-27.92 | $-19.90 | $-1.53 | $-1.14 | $-1.48 | $-1.43 | $-1.48 | $-1.22 | $-0.54 | $-0.55 |
| Surprise % | - | - | - | - | - | - | - | - | 0.05% | 0.04% | 0.04% | 0.08% | 0.06% | 0.04% | - | 0.93% | 1.38% | 1.00% | 1.04% | 0.95% | 1.27% | 1.38% | 0.91% |
According to undefined Wall Street analysts, Atara Biotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ATRA previous annual EPS of $NaN (undefined).
Atara Biotherapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BTAI | BioXcel Therapeutics | $0.63 | $13.00 | 1963.49% | Buy |
| ALLO | Allogene Therapeutics | $2.88 | $29.00 | 906.94% | Buy |
| FATE | Fate Therapeutics | $4.00 | $39.75 | 893.75% | Buy |
| KPTI | Karyopharm Therapeutics | $0.75 | $7.33 | 877.33% | Buy |
| XFOR | X4 Pharmaceuticals | $0.70 | $3.67 | 424.29% | Buy |
| HRTX | Heron Therapeutics | $1.90 | $7.00 | 268.42% | Buy |
| ITOS | iTeos Therapeutics | $12.12 | $37.67 | 210.81% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.48 | $7.00 | 182.26% | Buy |
| SANA | Sana Bio | $4.30 | $12.00 | 179.07% | Buy |
| TCRX | TScan Therapeutics | $5.45 | $12.00 | 120.18% | Buy |
| APLS | Apellis Pharmaceuticals | $35.53 | $75.38 | 112.16% | Buy |
| RCUS | Arcus Biosciences | $16.73 | $35.20 | 110.40% | Buy |
| MREO | Mereo BioPharma Group | $3.95 | $6.75 | 70.89% | Buy |
| CRBU | Caribou Biosciences | $2.10 | $3.00 | 42.86% | Buy |
| ATRA | Atara Biotherapeutics | $8.51 | $10.50 | 23.38% | Sell |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| HOOK | HOOKIPA Pharma | $4.78 | $3.00 | -37.24% | Buy |
ATRA Forecast FAQ
Is Atara Biotherapeutics a good buy?
No, according to 1 Wall Street analysts, Atara Biotherapeutics (ATRA) is considered a 'Sell'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of ATRA's total ratings.
What is ATRA's price target?
Atara Biotherapeutics (ATRA) average price target is $10.5 with a range of $3 to $18, implying a 23.38% from its last price of $8.51. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Atara Biotherapeutics stock go up soon?
According to Wall Street analysts' prediction for ATRA stock, the company can go up by 23.38% (from the last price of $8.51 to the average price target of $10.5), up by 111.52% based on the highest stock price target, and down by -64.75% based on the lowest stock price target.
Can Atara Biotherapeutics stock reach $13?
ATRA's highest twelve months analyst stock price target of $18 supports the claim that Atara Biotherapeutics can reach $13 in the near future.
What are Atara Biotherapeutics's analysts' financial forecasts?
Atara Biotherapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $109.18M (high $143.4M, low $71.13M), average EBITDA is $-101M (high $-78.627M, low $-123M), average net income is $-560M (high $-311M, low $-786M), average SG&A $236.43M (high $303.87M, low $162.25M), and average EPS is $-14.135 (high $-6.763, low $-20.726). ATRA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $67.75M (high $93.7M, low $38.53M), average EBITDA is $-13.55M (high $-7.705M, low $-18.74M), average net income is $-1.214B (high $-288M, low $-2.064B), average SG&A $173.55M (high $240.02M, low $98.69M), and average EPS is $-19.765 (high $-4.686, low $-33.602).
Did the ATRA's actual financial results beat the analysts' financial forecasts?
Based on Atara Biotherapeutics's last annual report (Dec 2023), the company's revenue was $8.57M, which missed the average analysts forecast of $44.02M by -80.52%. Apple's EBITDA was $-276M, beating the average prediction of $-92.253M by 199.18%. The company's net income was $-276M, missing the average estimation of $-2.739B by -89.92%. Apple's SG&A was $50.91M, missing the average forecast of $52.16M by -2.40%. Lastly, the company's EPS was $-2.61, missing the average prediction of $-52.364 by -95.02%. In terms of the last quarterly report (Dec 2023), Atara Biotherapeutics's revenue was $4.25M, beating the average analysts' forecast of $2.56M by 65.96%. The company's EBITDA was $-52.072M, beating the average prediction of $-512K by 10062.39%. Atara Biotherapeutics's net income was $-60.45M, missing the average estimation of $-683M by -91.15%. The company's SG&A was $10.39M, beating the average forecast of $6.56M by 58.28%. Lastly, the company's EPS was $-0.56, missing the average prediction of $-11.125 by -94.97%